(Q39708963)

English

Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 September 2017

Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. (English)

1 reference

Europe PubMed Central

14 September 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

object named as

Mohammad Ali

9

0 references

11

object named as

Firdausi Qadri

1 reference

Europe PubMed Central

14 September 2017

8

object named as

John Clemens

1 reference

Europe PubMed Central

14 September 2017

Fahima Chowdhury

5

object named as

Fahima Chowdhury

1 reference

Europe PubMed Central

14 September 2017

Md Saruar Bhuiyan

4

object named as

Md Saruar Bhuiyan

1 reference

Europe PubMed Central

14 September 2017

3

object named as

Farhana Khanam

1 reference

Europe PubMed Central

14 September 2017

Ashraful Islam Khan

6

object named as

Ashraful Islam Khan

1 reference

Europe PubMed Central

14 September 2017

Mohiul Islam Chowdhury

2

object named as

Mohiul Islam Chowdhury

1 reference

Europe PubMed Central

14 September 2017

Iqbal Ansary Khan

7

object named as

Iqbal Ansary Khan

1 reference

Europe PubMed Central

14 September 2017

author name string

Amit Saha

1

1 reference

Europe PubMed Central

14 September 2017

Alejandro Cravioto

10

1 reference

Europe PubMed Central

14 September 2017

language of work or name

0 references

publication date

9 September 2011

1 reference

Europe PubMed Central

14 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

14 September 2017

29

1 reference

Europe PubMed Central

14 September 2017

46

1 reference

Europe PubMed Central

14 September 2017

8285-8292

1 reference

Europe PubMed Central

14 September 2017

The origin of the Haitian cholera outbreak strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

The case for reactive mass oral cholera vaccinations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

The burden of diarrhoea, shigellosis, and cholera in North Jakarta, Indonesia: findings from 24 months surveillance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Endemic cholera in rural Bangladesh, 1966-1980.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Impact of rapid urbanization on the rates of infection by Vibrio cholerae O1 and enterotoxigenic Escherichia coli in Dhaka, Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18–36 months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Field trial of a locally produced, killed, oral cholera vaccine in Vietnam

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Evaluation of a probiotics, Bifidobacterium breve BBG-01, for enhancement of immunogenicity of an oral inactivated cholera vaccine and safety: A randomized, double-blind, placebo-controlled trial in Bangladeshi children under 5 years of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2011.08.108

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39708963&oldid=2089065862"